Please login to the form below

Not currently logged in
Email:
Password:

NOAC

This page shows the latest NOAC news and features for those working in and with pharma, biotech and healthcare.

FDA clears first generics of Pfizer/BMS’ anticoagulant Eliquis

FDA clears first generics of Pfizer/BMS’ anticoagulant Eliquis

Other directly-acting or ‘novel orally acting anticoagulants’ (NOACs) include Bayer/Johnson &Johnson's Xarelto (rivaroxaban) and Daiichi Sankyo's Lixiana/Savaysa – which like Eliquis are Factor Xa inhibitors – and Boehringer ... first generic

Latest news

  • The business case for patient engagement The business case for patient engagement

    But why not let a product’s evidence speak for itself? We found that patients’ confidence and propensity to promote can differ significantly, even among very comparable products such as NOACs. ... Over three days in spring 2019, we ran a short,

  • CHMP backs Lynparza in breast cancer, Dupixent in asthma CHMP backs Lynparza in breast cancer, Dupixent in asthma

    be the first reversal agent for novel oral anticoagulants (NOACs) that target factor Xa. ... So far, Boehringer Ingelheim’s rival NOAC Pradaxa (dabigatran) - which works by inhibiting thrombin - is the only NOAC on the market with a reversal agent

  • Bad news for Portola as CHMP considers Factor Xa drugs Bad news for Portola as CHMP considers Factor Xa drugs

    Portola Pharmaceuticals’ efforts to secure approval for its novel oral anticoagulant (NOAC) and reversal agent in Europe have hit another snag. ... In the meantime, Boehringer Ingelheim’s rival NOAC Pradaxa (dabigatran) - which works by inhibiting

  • Joerg Moeller to head Bayer R&D after operational shake-up Joerg Moeller to head Bayer R&D after operational shake-up

    It will also highlight its plans to expand the use of novel oral anticoagulant (NOAC) Xarelto (rivaroxaban) into coronary and peripheral artery disease, along with new-generation anticoagulants in mid-phase

  • BMS’ Opdivo defies naysayers with healthy growth BMS’ Opdivo defies naysayers with healthy growth

    Outside oncology, BMS’ top performer was novel oral anticoagulant Eliquis (apixaban), which grew 39% to $1.27bn, with Caforio claiming it is the most prescribed NOAC in the US, Japan and

More from news
Approximately 11 fully matching, plus 23 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • NOAC Education: Empowering Stroke Prevention

    The use of oral anticoagulants in patients with atrial fibrillation. NOAC reversal agents. ... PCM Scientific is always open to additional sources of funding support to expand the educational offerings of the NOAC education site.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months
...
July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...

Infographics